Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients

Cancer Research

Volumn 75, Issue 7, 2015, Pages 1205-1215

  Osman, Abdullah A ^a   Neskey, David M ^b   Katsonis, Panagiotis ^c   Patel, Ameeta A ^a   Ward, Alexandra M ^a   Hsu, Teng Kuei ^c   Hicks, Stephanie C ^d   McDonald, Thomas O ^e   Ow, Thomas J ^f   Alves, Marcus Ortega ^g   Pickering, Curtis R ^a   Skinner, Heath D ^a   Zhao, Mei ^a   Sturgis, Eric M ^a   Kies, Merrill S ^a   El Naggar, Adel ^a   Perrone, Federica ^h   Licitra, Lisa ^h   Bossi, Paolo ^h   Kimme, Marek ^e   Frederick, Mitchell J ^a   Lichtarge, Olivier ^c   Myers, Jeffrey N ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e Rice University   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g TUFTS MEDICAL CENTER   (United States)

^h NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; PROTEIN P53; TP53 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STAGING; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MOLECULAR EVOLUTION; MOUSE; MOUTH CANCER; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; TONGUE CANCER; TP53 GENE; ANIMAL; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENETICS; MALE; MIDDLE AGED; MUTATION; NUDE MOUSE; TONGUE NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; MALE; MICE, NUDE; MIDDLE AGED; MUTATION; TONGUE NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930967437     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2729     Document Type: Article

References (36)

1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-52.
3. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005;27:843-50.
4. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333:1154-57.
5. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-60
6. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998;12:2831-41.
7. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E, et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 1999;18:6845-54.
8. Wahl GM, Carr AM. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol 2001;3:E277-86.
9. Wulf GM, Liou YC, Ryo A, Lee SW, Lu KP. Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem 2002;277:47976-9.
10. Erber R, Conradt C, Homann N, Enders C, Finckh M, Dietz A, et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998;16:1671-9.
11. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007;357:2552-61.
12. Perrone F, Bossi P, Cortelazzi B, Locati L, Quattrone P, Pierotti MA, et al. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol 2010;28:761-6.
13. Tandon S, Tudur-Smith C, Riley RD, Boyd MT, Jones TM. A systematic review of p53 as a prognostic factor of survival in squamous cell carcinoma of the four main anatomical subsites of the head and neck. Cancer Epidemiol Biomarkers Prev 2010;19:574-87.
14. Lindenbergh-van der Plas M, Brakenhoff RH, Kuik DJ, Buijze M, Bloemena E, Snijders PJF, et al. Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2010;17:3733-41.
15. Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res 2011;17:7248-64.
16. Yigitbasi OG, Younes MN, Doan D, Jasser SA, Schiff BA, Bucana CD, et al. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 2004;64:7977-84.
17. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2012;18:290-300.
18. Sano D, Myers JN. Xenograft models of head and neck cancers. Head Neck Oncol 2009;1:32.
19. Kies MS, Boatright DH, Li G, Blumenschein G, El-Naggar AK, Lewin JS, et al. Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults. Head Neck 2012;34:1255-62.
20. Perrone F, Oggionni M, Birindelli S, Suardi S, Tabano S, Romano R, et al. TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. Int J Cancer 2003;105:196-203.
21. Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006;24:5630-6.
22. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 2003;100:8424-9.
23. Dietz S, Rother K, Bamberger C, Schmale H, Mossner J, Engeland K. Differential regulation of transcription and induction of programmed cell death by human p53-family members p63 and p73. FEBS Lett 2002;525:93-9.
24. Gadhikar MA, Sciuto MR, Ortega Alves MV, Pickering CR, Osman AA, Neskey DM, et al. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther 2013;12:1860-73.
25. Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, et al. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res 2005;65:7386-92.
26. Vikhanskaya F, Toh WH, Dullo I, Wu Q, Boominathan L, Ng HH, et al. p73 supports cellular growth through c-Jun-dependent AP-1 transactivation. Nat Cell Biol 2007;9:698-705.
27. Kakudo Y, Shibata H, Otsuka K, Kato S, Ishioka C. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 2005;65:2108-14.
28. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006;25:304-9.
29. Zalcenstein A, Stambolsky P, Weisz L, Muller M, Wallach D, Goncharov TM, et al. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 2003;22:5667-76.
30. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
31. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
32. Matsumoto M, Furihata M, Kurabayashi A, Ohtsuki Y. Phosphorylation state of tumor-suppressor gene p53 product overexpressed in skin tumors. Oncol Rep 2004;12:1039-43.
33. Matsumoto M, Furihata M, Ohtsuki Y. Posttranslational phosphorylation of mutant p53 protein in tumor development. Med Mol Morphol 2006;39:79-87.
34. Ge Zhou, Jiping Wang, Zhao M, Xie TX, Tanaka N, Sano D, et al. Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol Cell 2014;54:960-74.
35. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014;25:304-17.
36. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-9.